Cisplatin Pretreatment Enhances Anti-tumor Activity of Cytokine-induced Killer Cells

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2011 Jul 30

PMID 21799646

Citations 16

Authors

Xiang Huang

Yi-Tian Chen

Hai-Zhu Song

Gui-Chun Huang

Long-Bang Chen

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate whether cisplatin (DDP) enhances the anti-tumor activity of cytokine- induced killer (CIK) cells in a murine colon adenocarcinoma model.

Methods: Tumor size and weight served as indicators of therapeutic response. Immunohistochemistry was performed to observe intratumoral lymphocyte infiltration and tumor microvessel density. Changes in the percentage of regulatory T (Treg) cells within the spleens of tumor-bearing mice preconditioned with DDP were monitored using flow cytometry.

Results: A marked T cell-dependent, synergistic anti-tumor effect of the combined therapy was observed (1968 ± 491 mm³ vs 3872 ± 216 mm³; P = 0.003). Preconditioning chemotherapy with DDP augmented the infiltration of CD3+ T lymphocytes into the tumor mass and reduced the percentage of both intratumoral and splenic Treg cells.

Conclusion: Preconditioning with DDP markedly enhances the efficacy of adoptively transferred CIK cells, providing a potential clinical modality for the treatment of patients with colorectal cancer.

Citing Articles

Immunogenic chemotherapy: great potential for improving response rates.

Huang X, Ren Q, Yang L, Cui D, Ma C, Zheng Y Front Oncol. 2023; 13:1308681.

PMID: 38125944 PMC: 10732354. DOI: 10.3389/fonc.2023.1308681.

Inhibition of secretory leukocyte protease inhibitor (SLPI) promotes the PUMA-mediated apoptosis and chemosensitivity to cisplatin in colorectal cancer cells.

Wei Z, Liu G, Jia R, Zhang W, Li L, Zhang Y Discov Oncol. 2023; 14(1):1.

PMID: 36595102 PMC: 9810770. DOI: 10.1007/s12672-022-00535-9.

NK Cells in the Tumor Microenvironment as New Potential Players Mediating Chemotherapy Effects in Metastatic Melanoma.

Garofalo C, De Marco C, Cristiani C Front Oncol. 2021; 11:754541.

PMID: 34712615 PMC: 8547654. DOI: 10.3389/fonc.2021.754541.

Synergistic effects of low‑dose chemotherapy and T cells in renal cell carcinoma.

Xu D, Ding M, Tong P, Chong Y, Gu W, Li Y Oncol Rep. 2020; 44(3):897-908.

PMID: 32705278 PMC: 7388326. DOI: 10.3892/or.2020.7679.

Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC.

Lin W, Chen M, Hong L, Zhao H, Chen Q Front Oncol. 2018; 8:532.

PMID: 30519541 PMC: 6258806. DOI: 10.3389/fonc.2018.00532.

References

Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G . Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2007; 8(1):59-73. DOI: 10.1038/nri2216. View

Introna M, Borleri G, Conti E, Franceschetti M, Barbui A, Broady R . Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica. 2007; 92(7):952-9. DOI: 10.3324/haematol.11132. View

Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel M . Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst. 1997; 89(11):783-9. DOI: 10.1093/jnci/89.11.783. View

Merlo A, Casalini P, Carcangiu M, Malventano C, Triulzi T, Menard S . FOXP3 expression and overall survival in breast cancer. J Clin Oncol. 2009; 27(11):1746-52. DOI: 10.1200/JCO.2008.17.9036. View

Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C . Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009; 15(10):1170-8. DOI: 10.1038/nm.2028. View

Gellad Z, Provenzale D . Colorectal cancer: national and international perspective on the burden of disease and public health impact. Gastroenterology. 2010; 138(6):2177-90. DOI: 10.1053/j.gastro.2010.01.056. View

Wang L, Shu S, Plautz G . Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells. Cancer Res. 2005; 65(20):9547-54. DOI: 10.1158/0008-5472.CAN-05-1175. View

Gasser S, Orsulic S, Brown E, Raulet D . The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005; 436(7054):1186-90. PMC: 1352168. DOI: 10.1038/nature03884. View

Golovina T, Vonderheide R . Regulatory T cells: overcoming suppression of T-cell immunity. Cancer J. 2010; 16(4):342-7. DOI: 10.1097/PPO.0b013e3181eb336d. View

10.

Wu C, Jiang J, Shi L, Xu N . Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res. 2009; 28(6B):3997-4002. View

11.

Kerbel R, Kamen B . The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004; 4(6):423-36. DOI: 10.1038/nrc1369. View

12.

Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E . Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005; 106(6):2018-25. DOI: 10.1182/blood-2005-02-0642. View

13.

Bronte V, Mocellin S . Suppressive influences in the immune response to cancer. J Immunother. 2009; 32(1):1-11. DOI: 10.1097/CJI.0b013e3181837276. View

14.

Shapira S, Lisiansky V, Arber N, Kraus S . Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins. Expert Opin Investig Drugs. 2010; 19 Suppl 1:S67-77. DOI: 10.1517/13543781003737668. View

15.

Dudley M, Wunderlich J, Yang J, Sherry R, Topalian S, Restifo N . Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005; 23(10):2346-57. PMC: 1475951. DOI: 10.1200/JCO.2005.00.240. View

16.

Schmidt J, Eisold S, Buchler M, Marten A . Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma. Cancer Immunol Immunother. 2004; 53(11):1018-26. PMC: 11032841. DOI: 10.1007/s00262-004-0554-4. View

17.

Nishimura R, Baker J, Beilhack A, Zeiser R, Olson J, Sega E . In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood. 2008; 112(6):2563-74. PMC: 2532819. DOI: 10.1182/blood-2007-06-092817. View

18.

Sakaguchi S, Powrie F . Emerging challenges in regulatory T cell function and biology. Science. 2007; 317(5838):627-9. DOI: 10.1126/science.1142331. View

19.

Weng D, Zhou J, Zhou Q, Zhao M, Wang Q, Huang L . Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother. 2007; 31(1):63-71. DOI: 10.1097/CJI.0b013e31815a121b. View

20.

Colombo M, Piconese S . Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer. 2007; 7(11):880-7. DOI: 10.1038/nrc2250. View